Contact: Executives-Edge.com Rayk@capmarketsmedia.com

IPO Edge and CorpGov are pleased to provide a recap of the latest firesides at the Nasdaq held last May. The conversations included unsolicited takeover bids, diversified-land portfolios, the future of gaming, and data center buildouts, among other topics. Watch...

Download the Full Quarterly Update Report By Rayk Riechmann REX American Resources Corp. (NYSE: REX) reported its first quarter results, highlighting strong strategic execution that led to the nineteenth consecutive quarter of positive earnings despite a challenging macroeconomic environment. Long-term...

Contact: Executives-Edge.com Rayk@capmarketsmedia.com  

By Karen Roman Kohl’s Corp. (NYSE: KSS) shares rose 4% in early trade Thursday after the company said its first quarter loss narrowed to $15 million, or 13 cents a share, surpassing analysts’ expectations of 22 cents a share. Kohl’s...

By Exec Edge Editorial Staff BGN Group may not be an everyday presence in Americans’ lives the way more familiar energy companies are, but it may soon be, thanks to recent investments. The company, a global energy and commodities business,...

By Daniella Parra Accesso, investment manager and operator of multi-tenant office said the firm has signed more than 31,000 square feet in leases at Westlakes, a four-building, 455,000-square-foot, Class-A office complex located in the Philadelphia MSA. The leases include multiple...

By Daniella Parra Jeito Capital said it led a $65 million Series A funding round in ReproNovo, a biotech company focused on reproductive medicine and women’s health/. ReproNovo is addressing male and female infertility and uterine health advancing in RPN-001, an...

By Exec Edge Editorial Staff ICR, a global strategic communications and advisory firm, announced it is hosting its Conference Spotlight Series webinar today, May 21, 2025, from 12-1pm ET. The event will feature expert insights on capital markets readiness and communication...

By Daniella Parra Promontory Therapeutics said its Phase 2 meeting with the FDA cleared the way to launch a Phase 3 registrational trial of PT-112 monotherapy for metastatic castration-resistant prostate cancer. The company is a small, NYC-based biotech that, to...